Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

pradefovir

Known as: 9-(2-(4-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl)methoxyethyl)adenine, Remofovir 
A cyclodiester antiviral prodrug with specific activity against hepatitis B virus (HBV). Pradefovir is specifically metabolized in the liver by… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Pradefovir, a prodrug of PMEA, is under phase 2 clinical trial in China to evaluate its pharmacokinetic and pharmacodynamics… 
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Review
2010
Review
2010
Objective: To describe the current evidence for the use of oral antiretroviral (ARV) agents in the treatment of chronic hepatitis… 
  • table 1
Highly Cited
2008
Highly Cited
2008
Adefovir dipivoxil, a marketed drug for the treatment of hepatitis B, is dosed at submaximally efficacious doses because of renal… 
2007
2007
  • H. Tillmann
  • Current opinion in investigational drugs
  • 2007
  • Corpus ID: 43092749
Metabasis Therapeutics Inc (previously Ribapharm Inc) is developing pradefovir, an oral liver-targeting prodrug of adefovir… 
2006
2006
ABSTRACT Metabolic activation of pradefovir to 9-(2-phosphonylmethoxyethyl)adenine (PMEA) was evaluated by using cDNA-expressed… 
Review
2006
Review
2006
HepDirect prodrugs represent a novel class of cytochrome P450-activated prodrugs capable of targeting certain drugs to the liver… 
Highly Cited
2005
Highly Cited
2005
Targeting drugs to specific organs, tissues, or cells is an attractive strategy for enhancing drug efficacy and reducing side… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
2005
2005
The pharmacokinetics of pradefovir and adefovir, 9‐(2‐phosphonylmethoxyethyl) adenine (PMEA), was evaluated in healthy male… 
Review
2005
Review
2005
  • R. Gish
  • Seminars in liver disease
  • 2005
  • Corpus ID: 45683359
Currently approved treatments for chronic infection with hepatitis B virus (HBV) are limited by low rates of sustained response… 
2005
2005
ABSTRACT Single-dose pharmacokinetics and metabolism of [14C]remofovir was studied in rats and monkeys following intravenous (i.v…